…
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -47.41M | -12.51M | -28.81M | -17.61M | -0.57M |
| Minority interest | -0.41M | -0.42M | -3.55M | 45.20M | 64.50M |
| Net income | -48.62M | -16.38M | -81.02M | -14.30M | -0.78M |
| Selling general administrative | 209.81M | 170.52M | 138.38M | 103.20M | 72.26M |
| Gross profit | 209.66M | 186.39M | 135.19M | 107.38M | 83.29M |
| Reconciled depreciation | 35.47M | 39.30M | 30.98M | 16.51M | 12.47M |
| Ebit | 27.23M | 15.87M | -2.62M | 4.36M | 10.68M |
| Ebitda | 62.70M | 57.09M | 28.36M | 20.86M | 23.15M |
| Depreciation and amortization | 35.47M | 41.22M | 30.98M | 16.51M | 12.47M |
| Operating income | 27.23M | 15.87M | -2.62M | 4.36M | 7.75M |
| Other operating expenses | 894.41M | 916.66M | 783.24M | 705.25M | 517.59M |
| Interest expense | 27.37M | 24.70M | 26.30M | 14.49M | 8.02M |
| Tax provision | 1.21M | 3.87M | 52.22M | -3.31M | -0.66M |
| Interest income | - | - | - | 14.65M | 7.98M |
| Net interest income | -27.37M | -24.70M | -26.30M | -14.49M | -8.02M |
| Non recurring | 47.26M | - | - | - | - |
| Income tax expense | 1.21M | 3.87M | 52.22M | -3.31M | -0.66M |
| Total revenue | 921.51M | 932.53M | 780.05M | 709.43M | 528.61M |
| Total operating expenses | 182.56M | 170.52M | 138.38M | 103.20M | 72.26M |
| Cost of revenue | 711.85M | 746.13M | 644.86M | 602.05M | 445.33M |
| Total other income expense net | -74.64M | -28.39M | -26.19M | -21.97M | -3.58M |
| Net income from continuing ops | -48.62M | -16.38M | -81.02M | -14.30M | 0.09M |
| Net income applicable to common shares | -48.21M | -15.97M | -77.47M | -11.45M | -0.78M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 868.23M | 818.90M | 819.59M | 771.59M | 672.73M |
| Intangible assets | 159.73M | 172.48M | 190.66M | 213.00M | 119.96M |
| Other current assets | 12.64M | 8.24M | 8.90M | 8.31M | 7.07M |
| Total liab | 645.23M | 607.10M | 564.37M | 477.57M | 344.42M |
| Total stockholder equity | 221.21M | 209.92M | 252.83M | 262.41M | 283.11M |
| Other current liab | 34.06M | 21.15M | 28.20M | 20.26M | 13.04M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Retained earnings | -160.60M | -162.73M | -114.53M | -93.38M | -15.90M |
| Other liab | - | 1.02M | 0.46M | 1.40M | 0.12M |
| Good will | 199.40M | 183.31M | 231.11M | 231.16M | 231.04M |
| Other assets | - | 1.37M | 2.02M | 0.02M | 62.99M |
| Cash | 116.37M | 101.27M | 79.41M | 33.46M | 27.27M |
| Total current liabilities | 189.53M | 149.49M | 98.10M | 101.10M | 73.01M |
| Net debt | 351.93M | 370.67M | 401.25M | 354.33M | 252.46M |
| Short term debt | 16.20M | 15.35M | 14.85M | 12.71M | 8.44M |
| Short long term debt | 8.60M | 8.75M | 8.35M | 7.79M | 3.82M |
| Short long term debt total | 468.30M | 471.93M | 480.66M | 387.78M | 279.73M |
| Other stockholder equity | 383.49M | 374.85M | 368.01M | 356.44M | 300.12M |
| Property plant equipment | - | 73.39M | 97.10M | 63.15M | 73.31M |
| Total current assets | 430.83M | 370.11M | 298.69M | 242.30M | 185.42M |
| Net tangible assets | - | -145.86M | -168.95M | -181.75M | -67.89M |
| Net receivables | 142.51M | 118.00M | 113.95M | 102.75M | 71.38M |
| Long term debt | 437.82M | 443.28M | 448.47M | 355.98M | 251.38M |
| Inventory | 159.31M | 142.60M | 96.44M | 97.77M | 79.70M |
| Accounts payable | 139.26M | 113.00M | 55.06M | 68.13M | 51.54M |
| Noncontrolling interest in consolidated entity | - | 1.87M | 2.39M | 31.61M | 45.20M |
| Accumulated other comprehensive income | -1.71M | -2.22M | -0.68M | -0.69M | -1.13M |
| Common stock total equity | - | 0.03M | 0.03M | 0.03M | 0.03M |
| Retained earnings total equity | - | -162.73M | -114.53M | -93.38M | -15.90M |
| Non currrent assets other | 2.08M | 1.37M | 2.02M | 1.87M | 3.21M |
| Non current assets total | 437.39M | 448.78M | 520.90M | 529.30M | 487.31M |
| Capital lease obligations | 21.89M | 19.91M | 23.84M | 24.04M | 24.53M |
| Long term debt total | - | 443.28M | 448.47M | 355.98M | 254.71M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -11.97M | -26.14M | -118.02M | -195.03M | -100.00M |
| Change to liabilities | 51.24M | -12.13M | 25.98M | -7.51M | 18.59M |
| Total cashflows from investing activities | -11.97M | -26.14M | -118.02M | -195.03M | -100.00M |
| Net borrowings | -9.09M | 43.57M | -2.91M | 134.54M | 67.11M |
| Total cash from financing activities | -13.71M | 48.33M | 128.76M | 135.06M | 140.97M |
| Change to operating activities | -6.21M | 5.48M | 9.10M | -1.54M | 4.31M |
| Net income | -48.62M | -16.38M | -81.02M | -14.30M | 0.09M |
| Change in cash | 21.86M | 45.95M | 6.18M | -39.09M | 28.46M |
| Begin period cash flow | 79.41M | 33.46M | 27.27M | 66.36M | 37.90M |
| End period cash flow | 101.27M | 79.41M | 33.46M | 27.27M | 66.36M |
| Total cash from operating activities | 48.02M | 23.77M | -4.60M | 20.83M | -12.41M |
| Issuance of capital stock | - | - | 0.00M | 0.00M | 73.91M |
| Depreciation | 35.47M | 39.30M | 30.98M | 16.51M | 12.47M |
| Other cashflows from investing activities | - | 5.13M | -95.63M | -184.75M | -92.82M |
| Change to inventory | -46.30M | 1.28M | -17.85M | 30.45M | -36.61M |
| Change to account receivables | -4.14M | -11.20M | -31.65M | -14.12M | -14.21M |
| Sale purchase of stock | -3.86M | 0.01M | 9.27M | 2.32M | 75.34M |
| Other cashflows from financing activities | 58.24M | 647.33M | 968.80M | 813.12M | 535.22M |
| Change to netincome | 58.68M | 17.00M | 16.90M | 7.57M | 3.40M |
| Capital expenditures | 11.97M | 31.27M | 118.46M | 10.28M | 7.18M |
| Change receivables | -4.14M | -11.20M | -31.65M | -14.12M | -14.21M |
| Cash flows other operating | 1.69M | 2.11M | 52.07M | 2.24M | 3.86M |
| Exchange rate changes | - | - | - | - | -0.09M |
| Cash and cash equivalents changes | 22.34M | 45.96M | 6.14M | -39.13M | 28.56M |
| Change in working capital | 1.90M | -16.57M | -22.96M | 7.19M | -30.81M |
| Stock based compensation | 11.36M | 9.43M | 9.17M | 7.36M | 3.81M |
| Other non cash items | 47.32M | 4.50M | 7.73M | 7.54M | 2.87M |
| Free cash flow | 36.05M | -7.50M | -123.06M | 10.56M | -19.59M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
-0.23 0.70% |
32.85 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
169.42 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
- -% |
21.27 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
-0.54 1.24% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.
| Name | Title | Year Born |
|---|---|---|
| Mr. McCord Christensen | Chairman & CEO | 1972 |
| Mr. Michael A. Smith | Pres & COO | 1978 |
| Mr. Robert Michael Herrman | Exec. VP, Gen. Counsel & Corp. Sec. | 1969 |
| Mr. Zvi Glasman | Chief Financial Officer | 1964 |
| Mr. John Pearson | Sr. VP & Head of Services Division | NA |
| Mr. McCord Christensen | Chairman of the Board & CEO | 1972 |
| Mr. Michael A. Smith | President & COO | 1978 |
| Mr. William J. Carter | Executive VP & General Counsel | NA |
| Mr. John Pearson | Executive Vice President of Services & Manufactured Products | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.